| Drug | Formulations | Starting dose | Maintenance dose | Comments |
| Donepezil | Tablet or oral disintegrating tablet | 5 mg orally, once daily | 10 mg daily (increased after 4 to 6 weeks)* | |
| Galantamine | Immediate-release tablet or solution | 4 mg orally, twice daily | 12 mg twice daily (increased in monthly intervals by 4 mg twice-daily increments) | Give with meals. Maximum 8 mg twice daily with moderate renal or liver impairment. Do not use with severe renal or liver impairment. |
| Extended-release capsule | 8 mg orally, once daily | 24 mg once daily (increased in monthly intervals by 8 mg once-daily increments) | Maximum 12 mg once daily with moderate renal or liver impairment. Do not use with severe renal or liver impairment. | |
| Rivastigmine | Capsule | 1.5 mg orally, twice daily | 6 mg twice daily (increased in 2- to 4-week intervals by 1.5 mg twice-daily increments) | Give with meals. Slow and cautious titration with renal or liver impairment or low body weight. |
| Transdermal patch | 4.6 mg/24 hours | 9.5 to 13.3 mg/24 hours (increased in monthly intervals by 4.6 mg increments) | Can cause rash; rotate sites. Fewer side effects than capsule. Maximum dose 4.6 mg/24 hours with mild to moderate liver impairment or low body weight. Do not use with severe liver impairment. |
